Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xenetic BiosciencesSTU:3XB0 78 EV-to-FCF is 0.51 as of Jul. 21, 2026, which is 96% above its 10-year median of 0.26. GuruFocus rates STU:3XB0 with a GF Score™ of 78/100 and a GF Value™ of €4.66. The stock has 2 warning signs investors should review. Among 338 Biotechnology companies, Xenetic Biosciences ranks better than 83.43% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Xenetic Biosciences's Enterprise Value is €-0.80 Mil.
Xenetic Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.57 Mil. Therefore, Xenetic Biosciences's EV-to-FCF for today is 0.51.
The historical rank and industry rank for Xenetic Biosciences's EV-to-FCF or its related term are showing as below:
STU:3XB0'
s EV-to-FCF Range Over the Past 10 Years
Min: -77.77 Med: 0.26 Max: 10.32
Current: 0.5
During the past 13 years, the highest EV-to-FCF of Xenetic Biosciences was 10.32. The lowest was -77.77. And the median was 0.26.
STU:3XB0's EV-to-FCF is ranked better than 83.43% of 338
companies
in the Biotechnology industry
Industry Median: 15.02
vs STU:3XB0: 0.50
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xenetic Biosciences's PE Ratio (TTM) for today is calculated as:
Xenetic Biosciences's share price for today is €3.10.
Xenetic Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.032.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Xenetic Biosciences EV-to-FCF Related Terms
Xenetic Biosciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Xenetic Biosciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:3XB0 vs ACXP, SILO, GOVX: EV-to-FCF Comparison
For the Biotechnology subindustry, Xenetic Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenetic Biosciences EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Xenetic Biosciences's EV-to-FCF falls into.
Xenetic Biosciences's current Enterprise Value is €-0.80 Mil.
Xenetic Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenetic Biosciences (STU:3XB0) has a EV-to-FCF of 0.51 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Xenetic Biosciences and its competitors. This is 96% above median its historical median of 0.26. According to the industry distribution chart, Xenetic Biosciences ranks #56 out of 338 companies in the Biotechnology industry, placing it in the top 16.6%.
Is Xenetic Biosciences' EV-to-FCF too high?
Xenetic Biosciences' current EV-to-FCF of 0.51 is 96% above median its 10-year median of 0.26. The Biotechnology industry median EV-to-FCF is 15.02. Xenetic Biosciences' value of 0.51 is 96.6% below this industry median. Based on the distribution chart, Xenetic Biosciences ranks #56 out of 338 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xenetic Biosciences has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' EV-to-FCF compare to ACXP and SILO?
According to the Biotechnology industry distribution chart, Xenetic Biosciences ranks #56 out of 338 companies for EV-to-FCF. This places Xenetic Biosciences in the top 17% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 15.02. Xenetic Biosciences' value of 0.51 is 96.6% below this benchmark. While the company's 10-year median is 0.26 vs. the industry median of 15.02, Xenetic Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.02, based on 338 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xenetic Biosciences's current EV-to-FCF of 0.51 is 96.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Xenetic Biosciences and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xenetic Biosciences's current EV-to-FCF is 0.51, which is 96% above median its own 10-year median of 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Xenetic Biosciences (STU:3XB0) has a current EV-to-FCF of 0.51. The stock's GF Value™ is €4.66, compared to a current price of €3.10 — trading 33.5% below its estimated fair value. The current EV-to-FCF is 0.51, which is 96% above median its 10-year median of 0.26 and 96.6% below the Biotechnology industry median of 15.02. Xenetic Biosciences' overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Xenetic Biosciences (STU:3XB0), the current EV-to-FCF is 0.51 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xenetic Biosciences (STU:3XB0) Overvalued in 2026?
Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued.
The current stock price of €3.10 is trading 33.5% below its estimated GF Value™ of €4.66.
Key valuation signals for STU:3XB0:
EV-to-FCF: 0.51 (96% above median its 10-year median of 0.26)
GF Value™: €4.66 vs. price of €3.10 (33.5% below fair value)
Industry Position: 96.6% below the Biotechnology median (#56 of 338)
No single metric tells the full story. See the STU:3XB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
78GF Score
Get the complete analysis for STU:3XB0
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:3XB0 has been successfully added to your 
